In effort to assist pharma supply chain, company’s end goal is net-zero emissions by 2040
SkyCell, a manufacturer of pharma containers, has released its second annual sustainability report, outlining the progress made in achieving net-zero emissions within the entire supply chain and making pharma supply chains more sustainable. In 2021, the Swiss company successfully transitioned their operations to run solely on renewable electricity.
Reducing the carbon intensity of its shipments has been a vital part of the company’s emissions reduction plan. SkyCell notes that it has made progress, due to the improvement of its container design, material use, and production process. Its newest container, the 1500X, has achieved even greater weight and space efficiencies, weighing 379 kg (836 lbs).
SkyCell has tried to adhere to the principles of the circular economy by implementing processes to reuse, repair, refurbish, and recycle its containers to minimize environmental impacts. Last year, the company established its first in-house production center in Switzerland using robotic production, increasing the life cycle of containers with its improved build-quality.
“Helping to prevent climate change is one of my top missions as a father and engineer,” says Nico Ros, CTO and co-founder of SkyCell. “I wanted to prove that as engineers, we are capable of designing solutions that can redefine industry standards, cut CO2 emissions, and crucially reduce costs at the same time.”
The Digital Transformation Reshaping Hospitals and Medication Management
January 20th 2025Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.